Skip to main content

 Scientific publications

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Authors : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart M
Year : 2021
Journal : Breast Cancer Res Treat

Integrated molecular and immune phenotype of HER2-positive breast cancer and response to neoadjuvant therapy: a NeoALTTO exploratory analysis.

Authors : Pizzamiglio S, Ciniselli CM, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Izquierdo M, Nuciforo P, Huober J, Cappelletti V, Cinieri S, Piccart-Gebhart M, Daidone MG, Pruneri G, Colombo MP, Tagliabue E, Verderio P, Di Cosimo S
Year : 2021
Journal : Clin Cancer Res

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 125

A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.

Authors : Bardia A, Hurvitz SA, Rugo HS, Brufsky A, Cortes J, Loibl S, Piccart-Gebhart M, Cowden J, Spears P, Carey LA
Year : 2021
Journal : Future Oncol

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.

Authors : De Caluwé A, Buisseret L, Poortmans P, Van Gestel D, Salgado R, Sotiriou C, Larsimont D, Paesmans M, Craciun L, Drisis S, Vandekerckhove C, Reyal F, Veys I, Eiger D, Piccart-Gebhart M, Romano E, Ignatiadis M
Year : 2021
Journal : BMC Cancer
Volume : 21
Pages : 899

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.

Authors : Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart M, Korde LA, Goldhirsch A, Gelber Rd, Pagani O
Year : 2021
Journal : Breast
Volume : 59
Pages : 327-338

Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial.

Authors : Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Sotiriou C
Year : 2021
Journal : Clin Cancer Res

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations.

Authors : Conforti F, Pala L, Pagan E, Rocco EG, Bagnardi V, Montagna E, Peruzzotti G, De Pas T, Fumagalli C, Pileggi S, Pesenti C, Marchini S, Corso G, Marchio C, Sapino A, Graffeo R, Collet L, Aftimos P, Sotiriou C, Piccart-Gebhart M, Gelber Rd, Viale G, Colleoni M, Goldhirsch A
Year : 2021
Journal : Breast
Volume : 59
Pages : 94-101

Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative.

Authors : Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Nili Gal-Yam E, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, Hall P, Bonetti A, Larsson KF, Degiorgis M, Khodaverdi S, Greil R, Sverrisdottir A, Paoli M, Seyll E, Loibl S, Linderholm B, Zoppoli G, Davidson NE, Johannsson OT, Bedard PL, Loi S, Knox S, Cameron DA, Harbeck N, Lasa Montoya M, Brandão M, Vingiani A, Caballero C, Hilbers FS, Yates LR, Benelli M, Venet D, Piccart-Gebhart M
Year : 2021
Journal : Cancer Discov

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.

Authors : Agostinetto E, Rediti M, Piccart-Gebhart M, Fimereli D, Debien V, Aftimos P, Sotiriou C, de Azambuja E
Year : 2021
Journal : Cancers (Basel)
Volume : 13

Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.

Authors : Jackisch C, Cortazar P, Geyer CE Jr, Gianni L, Gligorov J, Machackova Z, Perez EA, Schneeweiss A, Tolaney SM, Untch M, Wardley A, Piccart-Gebhart M
Year : 2021
Journal : Cancer Treat Rev
Volume : 99
Pages : 102229

Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.

Authors : Piccart-Gebhart M, Kalinsky K, Gray R, Barlow WE, Poncet C, Cardoso F, Winer E, Sparano J
Year : 2021
Journal : Ann Oncol
Volume : 32
Pages : 1077-1082

Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.

Authors : Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber Rd, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, Mcfadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr
Year : 2021
Journal : N Engl J Med
Volume : 384
Pages : 2394-2405

Overcoming Barriers to Clinical Trials Cooperation: The Breast International Group Example.

Authors : Piccart-Gebhart M, Goulioti T, Straehle C, Cameron D
Year : 2021
Journal : Am Soc Clin Oncol Educ Book
Volume : 41
Pages : 1-9

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

Authors : Piccart M, van t Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kümmel S, Zoppoli G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT
Year : 2021
Journal : Lancet Oncol
Volume : 22
Pages : 476-488

Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Authors : Agostinetto E, Eiger D, Lambertini M, Ceppi M, Bruzzone M, Pondé N, Plummer C, Awada AH, Santoro A, Piccart-Gebhart M, de Azambuja E
Year : 2021
Journal : Eur J Cancer
Volume : 148
Pages : 76-91

CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.

Authors : Agostinetto E, Debien V, Marta GN, Lambertini M, Piccart-Gebhart M, de Azambuja E
Year : 2021
Journal : Eur J Clin Invest
Pages : e13535

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Authors : Piccart-Gebhart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber Rd, Viale G, Thomssen C
Year : 2021
Journal : J Clin Oncol
Volume : 39
Pages : 1448-1457

STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial.

Authors : Sonnenblick A, Agbor-Tarh D, de Azambuja E, Hultsch S, Izquierdo M, Liu M, Pruneri G, Harbeck N, Piccart-Gebhart M, Moreno-Aspita A, Granit RZ, Rouas G, Fahoum I, Sotiriou C
Year : 2021
Journal : Int J Cancer
Volume : 148
Pages : 1529-1535

Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Authors : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart-Gebhart M
Year : 2021
Journal : Breast Cancer Res Treat
Volume : 185
Pages : 107-116